NCT00715663View on ClinicalTrials.gov

Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes

CompletedOBSERVATIONAL
Enrollment

1,584

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
DiabetesDiabetes Mellitus, Type 2Delivery Systems
Interventions
DRUG

biphasic insulin aspart 30

No intervention is done. For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation

Trial Locations (1)

12520

Novo Nordisk Investigational Site, Jakarta

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00715663 - Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes | Biotech Hunter | Biotech Hunter